Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice [PDF]
, 2016 Diabetic patients suffer from a high rate of cardiovascular events and such risk increases with HbA1c. However, lowering HbA1c does not appear to yield the same benefit on macrovascular endpoints, as observed for microvascular endpoints. As the number of
Avogaro, Angelo +4 more
core +3 more sources
Diabetic kidney disease. new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "the natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function" [PDF]
, 2019 Recent epidemiological studies have disclosed heterogeneity in diabetic kidney disease (DKD). In addition to the classical albuminuric phenotype, two new phenotypes have emerged, i.e., “nonalbuminuric renal impairment” and “progressive renal decline ...
Barutta, Federica +7 more
core +1 more source
Journal of Clinical and Translational Science, 2022 OBJECTIVES/GOALS: Clinical trials of SGLT2 inhibitors in patients with heart failure (HF) have confirmed a reduction in hospitalization and death. Adoption of novel therapeutics has been slower in Black and female patients. We investigated utilization of
Apoorva Gangavelli +5 more
doaj +1 more source
Flozins in Reducing Cardiovascular and Metabolic Risk: A Literature Review
Quality in SportIntroduction Cardiovascular diseases (CVD) are a significant worldwide health issue, impacting millions of patients and being the primary cause of global illness and death.
Daria Sieniawska +2 more
doaj +1 more source
Scientific Reports, 2021 Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown impressive effects in reducing major vascular events in several randomized controlled trials (RCTs).
Wen-Hsuan Tsai +7 more
doaj +1 more source
Kidney & Blood Pressure Research, 2023 Background: Sodium-glucose cotransport protein 2 (SGLT2) inhibitors, a new type of glucose-lowering drug, have been well proved in several clinical studies for their glucose-lowering and nephroprotective effects, and the nephroprotective effects include ...
Jinfang Song, Xia Li, Jiang Ni
doaj +1 more source
Positron emission tomography of sodium glucose cotransport activity in high grade astrocytomas. [PDF]
, 2018 A novel glucose transporter, the sodium glucose cotransporter 2 (SGLT2), has been demonstrated to contribute to the demand for glucose by pancreatic and prostate tumors, and its functional activity has been imaged using a SGLT specific PET imaging probe,
Barrio, Jorge R +7 more
core +2 more sources
Meta-Analysis of Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes and All-Cause Mortality Among Patients With Type 2 Diabetes Mellitus [PDF]
, 2016 The benefit or risk of sodium glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular (CV) outcomes in patients with type 2 diabetes mellitus has not been established.
Cui, Wei +5 more
core +2 more sources
Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms [PDF]
, 2018 Hypertension and type 2 diabetes are common comorbidities. Hypertension is twice as frequent in patients with diabetes compared with those who do not have diabetes.
Guzik, Tomasz J. +2 more
core +1 more source
Renal and Cardiovascular Effects of sodium–glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF):protocol for a randomised controlled double-blind cross-over trial [PDF]
, 2017 Introduction: Type 2 diabetes (T2D) and heart failure (HF) are a frequent combination, where treatment options remain limited. There has been increasing interest around the sodium-glucose co-transporter 2 (SGLT2) inhibitors and their use in patients with
Baig, Fatima +7 more
core +2 more sources